Aberrant expression and kinase activity of Src have been found in many different tumors, including GC.4, 5 Previous studies have shown that phosphorylated mammalian target of rapamycin (p-mTOR) was significantly overexpressed in advanced GC patients' tumors and suggested that the PI3K/AKT/mTOR (phosphoinositide 3-kinase/AKT/mTOR) pathway is activated in GC with potential prognostic and predictive significance.6, 7 Aurora A overexpression has recently been reported in GC, and it was suggested to be associated with cancer progression and poor prognosis.8, 9, 10. The gene discussed is MTOR; the disease is gastric cancer.